INTRODUCTION
============

Parkinson\'s disease (PD), which is characterized by motor symptoms such as rigidity, hypokinesia, and tremor, is a neurological disorder caused by the loss of dopaminergic neurons in the substantia nigra that results in a decreased dopamine level in the striatum.[@B1] Moreover, the dopamine transporter (DAT), which is present on the presynaptic dopaminergic nerve terminal and controls dopamine level via the reuptake of dopamine in the synaptic cleft, is decreased with dopaminergic neurodegeneration of nigrostriatal neurons.[@B2][@B3] Since the uptake of ^123^I-ioflupane (^123^I-FP-CIT) in the striatum is correlated with DAT density, ^123^I-FP-CIT can be used to differentiate Parkinsonian syndromes with and without presynaptic dopaminergic loss.[@B3][@B4] A systematic review found that DAT imaging had a sensitivity of 100% in patients with a clinical or neuropathological diagnosis of PD.[@B5] It is well known that the DAT uptake of the striatum as measured by DAT imaging is correlated with the severity and duration of PD.[@B6][@B7] The annual reduction rate of striatal DAT uptake is between 6% and 13% in PD.[@B7]

PD was previously considered a nongenetic disease caused by environmental factors such as viral infection or neurotoxins.[@B8] However, following Polymeropoulos suggesting a genetic component of PD in 1997, various studies were conducted to identify the genetic factors affecting the etiology of PD using whole-exome sequencing and genome-wide association studies (GWAS).[@B8] Mutations causing PD have now been identified in 15 genes, including *SNCA*, *LRRK2*, and *MAPT*.[@B8]

Few studies have evaluated the correlation between genetic mutations and features of DAT imaging in PD patients. McNeill et al.[@B9] used ^123^I-FP-CIT single-photon-emission computed tomography (SPECT) to reveal that a striatal asymmetry index was higher in PD patients with *GBA* or *LRRK2* than in those with *PARKIN*, *PINK2*, and *SNCA*. Huertas et al.[@B10] reported that the striatal DAT availability as measured by ^123^I-FP-CIT SPECT in PD patients was associated with *SNCA* rs356219 and deleterious variants in *GBA*. However, to the best of our knowledge, no studies have evaluated the correlation between genetic mutations known to be risk factors in PD and chronological changes in striatal DAT availability in PD patients. The present study aimed to determine the association between the annual changes in DAT availability and single-nucleotide polymorphisms (SNPs) known to be risk factors in PD, in order to identify the prognostic value of genetic mutations in PD patients.

METHODS
=======

Subjects
--------

The data used in this study were obtained from the Parkinson\'s Progression Markers Initiative (PPMI) database ([www.ppmi-info.org/data](http://www.ppmi-info.org/data)); up-to-date information about the study is available at [www.ppmi-info.org](www.ppmi-info.org).[@B11] Males and females aged 30 years or older at screening were included. At baseline, patients with a PD diagnosis within the past 2 years, a Hoehn and Yahr stage not higher than II, a striatal dopamine deficit in ^123^I-FP-CIT SPECT, and who had not received treatment were included according to the PPMI criteria of PD groups. The following exclusion criteria are applied to the PPMI database: a clinical diagnosis of dementia, taking drugs within the previous 6 months that might interfere with ^123^I-FP-CIT SPECT, currently taking anticoagulants, having any other medical or psychiatric condition or laboratory abnormality, having taken investigational drugs or devices within 60 days prior to baseline, or showing evidence of clinically significant neurological disorders in magnetic resonance imaging. This study included PD patients who received two ^123^I-FP-CIT SPECT scans at both the initial screening and 12-month follow-up. The medical history, genotyping results, and ^123^I-FP-CIT SPECT scans were downloaded. The PPMI study was approved by the local Institutional Review Boards of all participating sites: Institute for Neurodegenerative Disorders, University of Pennsylvania, University of California, Los Angeles, Coriell Institute for Medical Research, Clinical Trials Coordination Center, Laboratory of Neurogenetics, National Institute on Aging National Institutes of Health, Institute for Neurodegenerative Disorders, Clinical Trials Statistical and Data Management Center, University of Iowa. Written informed consent was obtained from each subject at the time of enrollment for imaging data and clinical questionnaires. All of the study methods were performed in accordance with the relevant guidelines and regulations.

^123^I-FP-CIT SPECT and image analysis
--------------------------------------

^123^I-FP-CIT SPECT was performed during the screening visit for all subjects. SPECT scans were acquired 4.0±0.5 hr (mean±SD) after injecting 111--185 MBq ^123^I-FP-CIT. Subjects were pretreated with iodine solution or perchlorate prior to the injection in order to block uptake by the thyroid. Raw data were acquired into a 128×128 matrix, in steps of 3 or 4 degrees for the total projections. Raw projection data were reconstructed using iterative ordered subset expectation maximization with HERMES software (Hermes Medical Solutions, Stockholm, Sweden). The reconstructed images were transferred to PMOD software (PMOD Technologies, Zürich, Switzerland) for subsequent processing, including attenuation correction.

Downloaded scans were loaded using PMOD (version 3.6, PMOD Technologies) with the ^123^I-FP-CIT template.[@B12] The specific binding of ^123^I-FP-CIT regarding the DAT was calculated using a region-of-interest analysis. Standard sets of a volume of interest (VOI) defining the caudate nucleus and putamen based on the Automated Anatomical Labeling atlas[@B13] were used. The cerebellum was chosen as a reference region. The VOI template was applied to calculate specific binding ratios (SBRs) of the caudate nucleus and putamen as (target--cerebellum)/cerebellum. The annual percentage change in DAT availability was calculated as \[(SBR at 12-month follow-up)--(SBR at screening)\]/(SBR at screening)×100/\[(interval between 12-month follow-up and screening, in days)/365\].

Genotyping
----------

All samples were genotyped using the Illumina NeuroX array following the manufacturer\'s protocol (Illumina, San Diego, CA, USA). The Genotyping Analysis Module within Genome Studio (version 1.9.4; <https://support.illumina.com>) was used to analyze data. The genotype frequencies of the SNPs were in Hardy-Weinberg equilibrium (\>0.05). SNPs were removed if the minor allele frequency was less than 0.05. Twenty-three SNPs met the inclusion criteria for this study.

Clinical measurements
---------------------

To compare clinical features according to three subgroups of SNP, we used the results of the Movement-Disorder-Society-sponsored Unified Parkinson\'s Disease Rating Scale (MDS-UPDRS) parts II and III. The MDS-UPDRS score was obtained at the time of screening.

Statistical analysis
--------------------

Normality was examined using D\'Agostino-Pearson omnibus test. The paired *t*-test and the Wilcoxon test were used to compare differences between SBRs at screening and at the 12-month follow-up and in the annual percentage changes in the caudate nucleus and putamen. The Kruskal-Wallis test was used to compare the annual percentage changes in DAT availability for three subgroups of SNP. Since 23 SNPs met the inclusion criteria for this study, significance was set at α=0.05/23 (0.0022) to correct for multiple comparisons. Post-hoc analysis was performed for pairwise comparisons of subgroups using Dunn\'s test. The Kruskal-Wallis test was used to analyze the difference of the MDS-UPDRS score according to three subgroups of SNPs. Statistical analyses were performed using GraphPad Prism 7 for Mac OS X (GraphPad Software, San Diego, CA, USA), and MedCalc software package (version 12.6.0.0, MedCalc, Ostend, Belgium).

RESULTS
=======

This study included 150 PD patients (101 males and 49 females). The genotype and allele frequencies of the 23 SNPs in the PPMI database that met the inclusion criteria for this study are listed in [Table 1](#T1){ref-type="table"}. The SBRs of the caudate nucleus and putamen were 1.21±0.30 and 1.18±0.28, respectively, at screening, and 1.12±0.27 and 1.08±0.27 at the 12-month follow-up, thereby showing significant reductions for both structures (both *p*\<0.0001) ([Fig. 1](#F1){ref-type="fig"}). The mean interval between screening and the 12-month follow-up was 391.3 days. The annual percentage reduction in DAT availability was greater for the putamen (7.18%) than for the caudate nucleus (5.27%) (*p*=0.0417). The characteristics of the included subjects are summarized in [Table 2](#T2){ref-type="table"}.

None of the 23 SNPs exerted a statistically significant effect (*p*\<0.0022) on the decline of DAT availability in PD patients. However, we observed trends of association (*p*\<0.05) between three SNPs of two genes in terms of the annual percentage changes in DAT availability: 1) rs199347 on the putamen (*p*=0.0138), 2) rs356181 on the caudate nucleus (*p*=0.0105), and 3) rs3910105 on the caudate nucleus (*p*=0.0374). A post-hoc analysis revealed that DAT availability was reduced the most for 1) the putamen in the CC genotype of rs199347 (vs. CT, *p*=0.0199; vs. TT, *p*=0.0164), 2) the caudate nucleus in the TT genotype of rs356181 (vs. CC, *p*=0.0081), and 3) the caudate nucleus in the CC genotype of rs3910105 (vs. TT, *p*=0.0317) ([Fig. 2](#F2){ref-type="fig"}). However, the MDS-UPDRS score did not differ between the rs199347, rs356181, and rs3910105 SNPs.

DISCUSSION
==========

SNPs are variations in the positions of single nucleotides, and they have a frequency of at least 1% in the human genome.[@B14] An SNP can exert its affects at the transcriptional, translational, and posttranslational levels to result in alterations to gene expression and protein stability.[@B15] GWAS have identified numerous SNPs associated with cancer, infection, diabetes, and autoimmune, cardiovascular, gastrointestinal, and neuropsychiatric diseases.[@B15] Polymorphisms in the *SLC6A3* gene encoding DAT have been associated with DAT availability, and the number of tandem 9-repeats in the 3′ untranslated region of the gene was associated with greater striatal DAT availability than 10-repeats in normal subjects.[@B16] The rs2652511 and re2937639 SNPs in the *SLC6A3* gene were not associated with DAT availability.[@B16] However, the rs2652510 SNP with genotype GG in the *SLC6A3* gene was associated with the risk of PD.[@B17]

In the present study we demonstrated that the mean SBRs of the caudate nucleus and putamen differed significantly between at screening and at the 12-month follow-up. The annual reduction rate was 7.18% in the putamen and 5.27% in the caudate nucleus, which is consistent with previous findings.[@B7] No SNP significantly affected the decline of DAT availability in PD patients. However, association trends were observed in rs199347, rs356181, and rs3910105.

Nalls et al.[@B18] found that SNP rs199347 on chromosome 7, which was observed in the *GPNMB* gene, was correlated with PD in Caucasians. They demonstrated that rs199347 was associated with both methylation and expression changes in brain regions, and also showed that the risk allele (A) at rs199347 on chromosome 7 was associated with an increased expression of *NUPL2* as well as with decreased methylation of *GPNMB* in brain regions.[@B18] Those authors claimed that the risk at the locus containing rs199347 might be due to increased transcription of *NUPL2* and also be further bolstered by decreased methylation. Murthy et al.[@B19] also reported that rs199347 with major allele AA increased the expression of *GPNMB* in the brain cortex and putamen in PD patients. Among human brain cell types, the expression of *GPNMB* was highest in oligodendrocytes, followed by microglia and astrocytes.[@B19] A recent study demonstrated that *GPNMB* attenuates the astrocyte inflammatory response in rodents.[@B20] Neuroinflammation mediated by activated glial cells is a common feature of PD,[@B21] which suggests that the progression of PD via the activation of glial cells is attenuated by the increased expression of *GPNMB* through rs199347 with major allele AA. These results imply that the annual reduction rate of DAT availability was reduced the most at allele CC and the least at allele AA. However, rs199347 was not associated with PD in a Taiwanese population[@B22] or with PD in East Asians including residents of Singapore, Hong Kong, Malaysia, Korea, mainland China, and Taiwan.[@B23] The present study utilized the PPMI database, the enrolled patients of various ethnicities, and so the correlation between changes in DAT availability and rs199347 might have been underestimated. A large population study of Caucasians should be performed to validate the protective effect of rs199347 with allele AA of the GPNMB gene in the progression of PD.

SNPs rs356181 and rs3910105 on chromosome 4 were observed in the *SNCA* gene, which encodes α-synuclein,[@B24][@B25] α-Synuclein consists of 140 amino acid residues and is implicated in the etiology of neurodegenerative diseases such as Alzheimer\'s disease, PD, dementia with Lewy bodies, and multiple-system atrophy.[@B26] α-Synuclein is also considered to contribute to oligomers that are believed to play a key role in cell death and to be major components of Lewy bodies.26 Increased levels of *SNCA* mRNA have been reported in the midbrain and substantia nigra of PD patients compared with normal controls.[@B27] However, a study evaluating the association between cerebrospinal fluid biomarkers including for α-synuclein and rs356181 and rs3910105 genotypes found no association between them.[@B25]

The *SNCA* gene has two CpG islands: 1) CpG-1 (located in the first exon) and 2) CpG-2 (located in the first intron).[@B28] The methylation status of a CpG island is known to regulate *SNCA* in PD patients, and these islands are hypomethylated in PD patients compared with normal controls.[@B28] However, another study found no correlation between hypomethylation of the *SNCA*-intron 1 and the α-synuclein level.[@B29] In contrast, the risk alleles of both rs356181 and rs3910105 were associated with greater DNA methylation of the CpG island of the *SNCA* gene.[@B30] Similarly, DNA methylation of the CpG island of the *SNCA* gene and SNPs rs356181 and rs3910105 appeared to be related with PD progression in the present study.

To the best of our knowledge, this is the first study to have investigated the correlation between genetic mutations and chronological changes in DAT availability. However, this study was subject to some limitations: 1) DAT availability could be affected by dopaminergic medications, 2) the reduction in striatal DAT availability might not be continuous, 3) the retrospective design makes selection bias inevitable, 4) the enrolled patients had various ethnicities that would affect the SNPs, and 5) the number of enrolled patients was small.

In conclusion, no SNP showed a statistically significant effect on the decline of DAT availability in PD patients. However, we identified association trends: 1) rs199347 on the putamen, 2) rs356181 on the caudate nucleus, and 3) rs3910105 on the caudate nucleus. These findings indicate that the rs 199347, rs356181, and rs3910105 SNPs might affect the progression of PD.
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###### Genotype frequencies for alleles

![](jcn-15-102-i001)

  SNP           Genotype (*n*)   MAF                 
  ------------- ---------------- --------- --------- ------
  rs10797576    CC (112)         CT (36)   TT (2)    0.13
  rs11060180    AA (50)          AG (69)   GG (31)   0.44
  rs11158026    CC (63)          CT (75)   TT (12)   0.33
  rs115462410   CC (128)         CT (21)   TT (1)    0.08
  rs11724635    AA (53)          AC (65)   CC (32)   0.43
  rs11868035    AA (13)          AG (61)   GG (76)   0.34
  rs12456492    AA (71)          AG (67)   GG (12)   0.30
  rs12637471    AA (5)           AG (49)   GG (96)   0.20
  rs14235       AA (25)          AG (75)   GG (49)   0.42
  rs17649553    CC (103)         CT (43)   TT (4)    0.17
  rs1955337     GG (109)         GT (38)   TT (3)    0.15
  rs199347      CC (20)          CT (74)   TT (56)   0.38
  rs2414739     AA (81)          AG (60)   GG (9)    0.26
  rs329648      CC (62)          CT (62)   TT (26)   0.38
  rs34311866    AA (85)          AG (53)   GG (12)   0.26
  rs356181      CC (43)          CT (75)   TT (32)   0.46
  rs3910105     CC (29)          CT (74)   TT (47)   0.44
  rs55785911    AA (22)          AG (73)   GG (55)   0.39
  rs591323      AA (12)          AG (65)   GG (73)   0.30
  rs6430538     CC (46)          CT (68)   TT (36)   0.47
  rs6812193     CC (64)          CT (69)   TT (17)   0.34
  rs76904798    CC (106)         CT (43)   TT (1)    0.15
  rs823118      CC (26)          CT (81)   TT (43)   0.44

MAF: minor allele frequency, SNP: single-nucleotide polymorphism.

###### Characteristics of the study subjects

![](jcn-15-102-i002)

  Characteristic                                       Value
  ---------------------------------------------------- -------------
  Age (years)                                          63.1±9.3
  Sex (male/female)                                    101/49
  SBR at screening                                     
   Caudate nucleus                                     1.21±0.30
   Putamen                                             1.18±0.28
  SBR at 12-month f/u                                  
   Caudate nucleus                                     1.12±0.27
   Putamen                                             1.08±0.27
  Annual percentage change (%)                         
   Caudate nucleus                                     −5.27±15.82
   Putamen                                             −7.18±12.48
  Interval between screening and 12-month f/u (days)   391.3±53.5

Data are mean±SD values.

f/u: follow-up, SBR: specific binding ratio.
